#### As Offered

## 131st General Assembly Regular Session 2015-2016

H. R. No. 428

**Representatives Antonio, LaTourette** 

### A RESOLUTION

To urge the Congress of the United States, the	1
United States Food and Drug Administration, and	2
the National Institutes of Health to address the	3
cost and availability of cancer drugs.	4

# BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE STATE OF OHIO:

WHEREAS, The American Cancer Society estimates that about	5
1,685,210 new cancer cases will be diagnosed in 2016 and	6
approximately 595,690 Americans are expected to die from cancer	7
in 2016 (approximately 1,630 people per day); and	8
WHEREAS, The National Institutes of Health estimates that	9
the overall cost of cancer in 2013 for direct medical costs was	10
nearly \$125 billion and direct medical costs are expected to	11
reach at least \$158 billion by 2020; and	12
WHEREAS, Each year, approximately 650,000 cancer patients	13
receive chemotherapy in outpatient oncology clinics in the	14
United States, with many receiving drugs combined together in	15
groups of two to four for combination chemotherapy; and	16
WHEREAS, Global spending on cancer drugs has increased from	17
\$37 billion a decade ago to \$91 billion in 2013; and	18
WHEREAS, Many insurance plans place cancer medications into	19
payment tiers that require the biggest out-of-pocket costs by	20

#### H. R. No. 428 As Offered

patients, often 20% to 40% of the cost of the medications; and	21
WHEREAS, It is estimated that one in eight people with	22
advanced cancer turn down recommended care because of the cost;	23
now therefore be it	24
RESOLVED, That we, the members of the House of	25
Representatives of the 131st General Assembly of the State of	26
Ohio, urge the Congress of the United States, the United States	27
Food and Drug Administration, and the National Institutes of	28
Health to address the cost and availability of cancer drugs; and	29
be it further	30
RESOLVED, That the Clerk of the House of Representatives	31
transmit duly authenticated copies of this resolution to the	32
Speaker and Clerk of the United States House of Representatives,	33
the President Pro Tempore and Secretary of the United States	34
Senate, the Commissioner of the United States Food and Drug	35
Administration, and the Director of the National Institutes of	36
Health.	37

Page 2